Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues

The decision to pursue a monoclonal antibody (mAb) as a therapeutic for disease intervention requires the assessment of many factors, such as target-biology, including the total target burden and its accessibility at the intended site of action, as well as mAb-specific properties like binding affini...

Descripción completa

Detalles Bibliográficos
Autores principales: Conner, Kip P., Pastuskovas, Cinthia V., Soto, Marcus, Thomas, Veena A., Wagner, Mylo, Rock, Dan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188401/
https://www.ncbi.nlm.nih.gov/pubmed/32310023
http://dx.doi.org/10.1080/19420862.2020.1746520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188401/
https://www.ncbi.nlm.nih.gov/pubmed/32310023
http://dx.doi.org/10.1080/19420862.2020.1746520

Ejemplares similares